VRNA logo

VRNAVerona Pharma Plc American Depositary

$0.00
$0.00
(0.00%)
Today
Updated:
Reported EarningsJul 31
Mkt Cap$9.19B
Vol1.87M
News
all
press releases
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium
Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.
Stocktwits
News Placeholder
More News
News Placeholder
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Zacks
News Placeholder
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Zacks
News Placeholder
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Zacks
News Placeholder
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Zacks
News Placeholder
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.
Zacks
News Placeholder
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Zacks
News Placeholder
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
Zacks
News Placeholder
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
Zacks
<
1
2
...
>

Advertisement|Remove ads.